CSE bulletin 2023-1009

The common shares of Mydecine Innovations Inc. have been approved for listing on the Canadian Securities Exchange.

Listing and disclosure documents will be available on the CSE website on the trading date.

Mydecine Innovations Group is a biopharmaceutical company founded to increase physicians' access to serotonin-modulating medicine. Recent research has demonstrated the therapeutic potential of psychedelic substances such as psilocybin and MDMA (3,4-methylenedioxy-methamphetamine) for treating intractable conditions such as pain, anxiety, depression, addiction and PTSD (posttraumatic stress disorder), along with neurodegenerative disorders. Mydecine believes these compounds can be safer, more effective and more accessible for patients and medical professionals through modern drug chemistry paired with artificial intelligence (AI). Mydecine is developing innovative medications for target indications with high mortality rates that have lacked innovation for decades and are controlled by dominant corporations.

Issuer:  Mydecine Innovations Group

Security type:  common shares

Symbol:  MYCO

Number of securities issued and outstanding:  45,207,458

Number of securities reserved for issuance:  22,608,492

CSE sector:  diversified industries

Cusip No.:  62849F 20 0

ISIN:  CA 62849F 20 0 8

Board lot:  500

Trading currency:  Canadian dollar

Listing date:  Oct. 6, 2023

Other exchanges:  not applicable

Fiscal year-end:  Dec. 31

Transfer agent:  National Securities Administrators Ltd.

The exchange is accepting market-maker applications for MYCO.